Frigault MJ, et al. Abstract 8015. Presented at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.
Arcellx funded this study. Frigault reports consultant/advisory board roles with Arcellx, Bristol Myers Squibb/Juno Therapeutics, Foundation Medicine, Gilead Sciences, Incyte and Novartis, and ownership of intellectual property related to chimeric antigen receptors and T cell manufacturing. Please see the abstract for all other researchers’ relevant financial disclosures.